Functional studies demonstrate that PRMT1 regulates IGF2BP2 expression, which in turn mediates PRMT1‐driven oncogenic effects, including tumor proliferation, apoptosis resistance, and CBP sensitivity. This evidence concerns the gene IGF2BP2 and neoplasm.